Physician profile
Robert E Clark
NPI 1033372727
$12,415.00
in general payments reported to CMS, 2019-2025
42 companies · $2,358 in 2025
The $2,358 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,629 · 2020: $375 · 2021: $708 · 2022: $1,998 · 2023: $2,879 · 2024: $2,469 · 2025: $2,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,595 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,594.57 |
| Education | $110.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,422.76 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $1,889.92 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,196.23 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $672.86 | 2019-2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $419.64 | 2022-2025 | Dupixent |
| Pfizer INC. | $409.01 | 2019-2024 | |
| Celgene Corporation | $403.05 | 2021-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $371.33 | 2021-2024 | Zeposia |
| Genzyme Corporation | $329.36 | 2022-2025 | |
| Ucb, INC. | $199.65 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $182.91 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $181.82 | 2022-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $178.02 | 2022-2023 | |
| Braintree Laboratories, INC. | $150.09 | 2019-2025 | Sutab, Suflave |
| Organon LLC | $127.84 | 2022-2023 | Renflexis, Hadlima |
Show all 41 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,375.19 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.